Jane Street’s NeuroSense Therapeutics NRSN Stock Holding History

Jane Street’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,434	Closed	-$21.6K	–	12637
2026 Q1	$21.6K	Buy	+1,434	New	+$25.6K	﹤0.01%	11184
2025 Q3	–	Sell	-1,434	Closed	-$54.2K	–	11455
2025 Q2	$54.2K	Buy	+1,434	New	+$41.6K	﹤0.01%	9150
2025 Q1	–	Sell	-3,232	Closed	-$77.6K	–	10243
2024 Q4	$77.6K	Buy	+3,232	New	+$74.3K	﹤0.01%	8857
2022 Q3	–	Sell	-3,862	Closed	-$261K	–	10199
2022 Q2	$261K	Buy	3,862 +1,687	+78%	+$63.9K	﹤0.01%	7821
2022 Q1	$173K	Buy	+2,175	New	+$104K	﹤0.01%	9128

Other funds holding NRSN

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jane Street's NRSN Position: Q2 2026 in Review

Jane Street sold out of NeuroSense Therapeutics (NRSN) in Q2 2026, closing a stake of 1,434 shares — an estimated $21.6K sold.

Jane Street first reported a position in NRSN in Q1 2022 and held it in 5 quarters. The position peaked at $261K in Q2 2022. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

Jane Street reported no remaining NeuroSense Therapeutics position as of Q2 2026 after selling out during the quarter.
Jane Street sold 1,434 NeuroSense Therapeutics shares in Q2 2026, an estimated $21.6K.
Jane Street first reported a position in NeuroSense Therapeutics in Q1 2022 and held it in 5 quarters.
Jane Street's NeuroSense Therapeutics position peaked at $261K in Q2 2022.
12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.